Modern view on the place of riociguat in the treatment of pulmonary hypertension

Modern view on the place of riociguat in the treatment of pulmonary hypertension

Show other versions (1)

Current research is aimed at studying the fundamental therapeutic targets and discovering new drugs acting on previously set targets. Until recently, the only therapeutic strategy to influence the molecular pathway of nitric oxide (NO) - soluble guanylate cyclase (sGC) - cyclic guanosine monophospha...

Full description

Bibliographic Details
Main Authors:	Z S Valieva, I N Taran, T V Martynyuk, I Ye Chazova
Format:	Article
Language:	Russian
Published:	"Consilium Medicum" Publishing house 2018-04-01
Series:	Терапевтический архив
Subjects:	pulmonary arterial hypertension therapy optimization riociguat
Online Access:	https://ter-arkhiv.ru/0040-3660/article/viewFile/32470/pdf

Similar Items

Modern view on the place of riociguat in the treatment of pulmonary hypertension
by: Z.S. Valieva, et al.
Published: (2018-04-01)

The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat
by: S. E. Gratsianskaya, et al.
Published: (2020-10-01)

Features of clinical, functional and hemodynamics profile, medical treatment and prognosis evaluation in patients with inoperable chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension according to the Russian registry
by: I E Chazova, et al.
Published: (2019-09-01)

Treatment of patients with chronic thromboembolic pulmonary hypertension: focus on riociguat
by: Smith ZR, et al.
Published: (2016-06-01)

Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?
by: N. H. Kim
Published: (2010-03-01)

Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension
by: Lian TY, et al.
Published: (2017-04-01)

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
by: Alberto M. Marra, et al.
Published: (2018-12-01)

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
by: Vallerie V. McLaughlin, et al.
Published: (2017-12-01)

Riociguat is a novel medication for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
by: N. A. Tsareva, et al.
Published: (2016-12-01)

Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences
by: Asger Andersen, et al.
Published: (2017-01-01)

Riociguatas the first innovative guanylatecyclase stimulators class drugs for pulmonary arterial hypertension patients treatment
by: I E Chazova, et al.
Published: (2013-12-01)

Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy
by: H. A. Ghofrani, et al.
Published: (2009-03-01)

Beneficial effects of riociguat on hemodynamic responses to exercise in CTEPH patients after balloon pulmonary angioplasty – A randomized controlled study
by: Tatsuo Aoki, et al.
Published: (2020-08-01)

Experience of the management of patients with pulmonary hypertension in the Republic of Karelia
by: Vadim A Ryabkov, et al.
Published: (2019-09-01)

July 2013 pulmonary journal club
by: Mathew M
Published: (2013-07-01)

The impact of riociguat on clinical parameters and quality of life in patients with chronic thromboembolic pulmonary hypertension - results of a retrospective clinical registry
by: Pavel Jansa, et al.
Published: (2021-06-01)

A patient with severe idiopathic pulmonary arterial hypertension: Is there a way out?
by: N A Tsareva, et al.
Published: (2017-09-01)

Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Chronic thromboembolic pulmonary hypertension
by: Eckhard Mayer, et al.
Published: (2014-01-01)

Possibility of complex medicamental and endovascular treatment of pulmonary hypertension in Takayasu arteritis with predominant pulmonary arteries’ lesion
by: T. V. Маrtynuk, et al.
Published: (2020-06-01)

Soluble Guanylate Cyclase Stimulators for Chronic Thromboembolic Pulmonary Hypertension Patients Treatment: New Data
by: M. A. Simakova, et al.
Published: (2020-05-01)

Treatment Strategy Options in Inoperable Chronic Thromboembolic Pulmonary Hypertension Patients
by: N. V. Marukyan, et al.
Published: (2021-05-01)

EFFICACY OF MULTIDISCIPLINARY MANAGEMENT OF PULMONARY HYPERTENSION
by: I. R. Gaisin, et al.
Published: (2017-02-01)

September 2013 pulmonary journal club: riociguat; pay the doctor
by: Robbins RA
Published: (2013-09-01)

The development of a screening questionnaire to improve the early detection of pulmonary arterial hypertension
by: Z S Valieva, et al.
Published: (2014-12-01)

Bosentan use in pulmonary arterial hypertension: Russian and foreign experience
by: Z S Valieva, et al.
Published: (2017-08-01)

The validation of the questionnaire for the early detection of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
by: Z S Valieva, et al.
Published: (2016-03-01)

Switching Strategy in the Management of Patients with Pulmonary Arterial Hypertension. The REPLACE Study Results
by: E. V. Filippov
Published: (2020-12-01)

Survival of patients with pulmonary arterial hypertension during therapy PAH-specific drugs
by: D Yu Platonov, et al.
Published: (2017-12-01)

Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry
by: I E Chazova, et al.
Published: (2019-01-01)

The validation of the questionnaire for the early detection of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
by: Valieva Z.S., et al.
Published: (2016-01-01)

New horizons for the use of the second generation of endothelin receptor antagonist macitentan in patients with pulmonary hypertension
by: T V Martynyuk, et al.
Published: (2018-04-01)

Repurposing Riociguat for Treatment of Refractory Angina Resulting From Coronary Spasm
by: Valeria Martínez Pereyra, MS, et al.
Published: (2021-03-01)

Revisiting a Distinct Entity in Pulmonary Vascular Disease: Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
by: Munish Sharma, et al.
Published: (2021-04-01)

Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension
by: John W. Swisher, PhD, MD, et al.
Published: (2017-01-01)

ASPECTS OF MODERN COMBINATION SPECIFIC THERAPY OF PULMONARY ARTERIAL HYPERTENSION: THE PROS AND CONS
by: T. V. Martynyuk, et al.
Published: (2017-12-01)

New horizons for the use of the second generation of endothelin receptor antagonist macitentan in patients with pulmonary hypertension
by: T.V. Martynyuk, et al.
Published: (2018-04-01)

Demographic and clinical differences between idiopathic and scleroderma-related pulmonary arterial hypertension: Russian National Registry analysis
by: N N Yudkina, et al.
Published: (2016-06-01)

A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers
by: Vivek Nagaraja, et al.
Published: (2019-09-01)

Endothelin receptor antagonist bosentan role in modern strategy for patients with pulmonary arterial hypertension treatment
by: O A Arkhipova, et al.
Published: (2018-06-01)

Quality of life in patients with idiopathic pulmonary hypertension: the first experience of trimetazidine
by: E G Kuznetsova, et al.
Published: (2017-06-01)